These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29582427)

  • 21. Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.
    Bongiorno MR; Crimi N; Corrao S; Allotta A; Arena A; Brusca I; Heffler E; Malara G; Milioto M; Pistone G; Porto M; Raia E; Valenti G
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):703-707. PubMed ID: 27720581
    [No Abstract]   [Full Text] [Related]  

  • 22. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life treatment of cholinergic urticaria with omalizumab.
    Altrichter S; Chuamanochan M; Knoth H; Asady A; Ohanyan T; Metz M; Maurer M
    J Allergy Clin Immunol; 2019 Feb; 143(2):788-791.e8. PubMed ID: 30312709
    [No Abstract]   [Full Text] [Related]  

  • 24. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
    Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
    [No Abstract]   [Full Text] [Related]  

  • 25. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria.
    Maurer M; Kolkhir P; Moñino-Romero S; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668
    [No Abstract]   [Full Text] [Related]  

  • 28. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab.
    Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J
    J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
    Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 33. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
    Casale TB; Win PH; Bernstein JA; Rosén K; Holden M; Iqbal A; Trzaskoma BL; Yang M; Antonova EN; Murphy T; Scarupa MD; Sofen H; Kaplan A
    J Am Acad Dermatol; 2018 Apr; 78(4):793-795. PubMed ID: 29037993
    [No Abstract]   [Full Text] [Related]  

  • 34. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.
    Asero R; Marzano AV; Ferrucci S; Genovese G; Cugno M
    Allergy; 2019 Dec; 74(12):2538. PubMed ID: 31165493
    [No Abstract]   [Full Text] [Related]  

  • 36. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 37. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients.
    Vadasz Z; Tal Y; Rotem M; Shichter-Confino V; Mahlab-Guri K; Graif Y; Kessel A; Agmon-Levin N; Maoz-Segal R; Kivity S; Benor S; Lachover-Roth I; Zeldin Y; Stein M; Toker O; Hassoun G; Bezalel-Rosenberg S; Toubi E; Asher I; Sthoeger Z;
    J Allergy Clin Immunol Pract; 2017; 5(6):1743-1745. PubMed ID: 28988786
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
    Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H
    J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
    Harris JM; Cabanski CR; Scheerens H; Samineni D; Bradley MS; Cochran C; Staubach P; Metz M; Sussman G; Maurer M
    J Allergy Clin Immunol; 2016 Dec; 138(6):1730-1732. PubMed ID: 27567329
    [No Abstract]   [Full Text] [Related]  

  • 40. Tolerance to nonsteroidal anti-inflammatory drugs and alcohol after omalizumab treatment in a patient with chronic urticaria.
    Walters KM; White AA
    Ann Allergy Asthma Immunol; 2016 Nov; 117(5):559-561. PubMed ID: 27788887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.